Breaking News

Novo Nordisk Exits Inflammatory R&D

September 3, 2014

Will focus efforts on diabetes prevention and treatment

Novo Nordisk has decided to discontinue all R&D activities within inflammatory disorders and will increase efforts within diabetes prevention and treatment, obesity and diabetes complications.

Related Contract Manufacturing:

blog comments powered by Disqus